{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:40:38Z","timestamp":1792370438851,"version":"4.4.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06563-0","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:27Z","timestamp":1784699667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nucleotide excision repair in tumor response to DNA-damaging anticancer therapies: a comprehensive review"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6786-5707","authenticated-orcid":false,"given":"Bartosz","family":"Ma\u0107kowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Ostrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kozikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kulcenty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Golusi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Suchorska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"6563_CR1","first-page":"959","volume":"14","author":"R Altaha","year":"2004","unstructured":"Altaha R, Liang X, Yu J, Jie, Reed E (2004) Excision repair cross complementing-group 1: gene expression and platinum resistance (review) parameters in human breast cancer. Int J Mol Med 14:959\u2013970","journal-title":"Int J Mol Med"},{"key":"6563_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","volume":"189","author":"M Baretti","year":"2018","unstructured":"Baretti M, Le DT (2018) DNA mismatch repair in cancer. Pharmacol Ther 189:45\u201362","journal-title":"Pharmacol Ther"},{"key":"6563_CR3","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/bjc.2013.576","volume":"109","author":"JE Bauman","year":"2013","unstructured":"Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN et al (2013) ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer 109:2096\u20132105","journal-title":"Br J Cancer"},{"key":"6563_CR4","doi-asserted-by":"publisher","unstructured":"B\u00f6rcs\u00f6k J, Gopaul D, Devesa-Serrano D, Mooser C, Jonsson N, Cagiada M et al (2025a) Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer. J Clin Invest 135. https:\/\/doi.org\/10.1172\/JCI186688","DOI":"10.1172\/JCI186688"},{"key":"6563_CR5","doi-asserted-by":"publisher","first-page":"e186688","DOI":"10.1172\/JCI186688","volume":"135","author":"J B\u00f6rcs\u00f6k","year":"2025","unstructured":"B\u00f6rcs\u00f6k J, Gopaul D, Devesa-Serrano D, Mooser C, Jonsson N, Cagiada M et al (2025b) Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer. J Clin Invest 135:e186688","journal-title":"J Clin Invest"},{"key":"6563_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.canlet.2014.01.005","volume":"346","author":"NA Bowden","year":"2014","unstructured":"Bowden NA (2014) Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Lett 346:163\u2013171","journal-title":"Cancer Lett"},{"key":"6563_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.canrad.2021.02.001","volume":"25","author":"I Brook","year":"2021","unstructured":"Brook I (2021) Early side effects of radiation treatment for head and neck cancer. Cancer\/Radioth\u00e9rapie 25:507\u2013513","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"6563_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/biotech13010003","volume":"13","author":"J Chen","year":"2024","unstructured":"Chen J, Potlapalli R, Quan H, Chen L, Xie Y, Pouriyeh S et al (2024) Exploring DNA damage and repair mechanisms: a review with computational insights. BioTech 13:3","journal-title":"BioTech"},{"key":"6563_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12885-019-6496-1","volume":"20","author":"Z Cierna","year":"2020","unstructured":"Cierna Z, Miskovska V, Roska J, Jurkovicova D, Pulzova LB, Sestakova Z et al (2020) Increased levels of XPA might be the basis of cisplatin resistance in germ cell tumours. BMC Cancer 20:17","journal-title":"BMC Cancer"},{"key":"6563_CR13","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-10-0263","volume":"9","author":"M D\u2019Incalci","year":"2010","unstructured":"D\u2019Incalci M, Galmarini CM (2010) A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 9:2157\u20132163","journal-title":"Mol Cancer Ther"},{"key":"6563_CR12","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1101\/gad.13.7.768","volume":"13","author":"WL De Laat","year":"1999","unstructured":"De Laat WL, Jaspers NGJ, Hoeijmakers JHJ (1999) Molecular mechanism of nucleotide excision repair. Genes Dev 13:768\u2013785","journal-title":"Genes Dev"},{"key":"6563_CR38","doi-asserted-by":"publisher","first-page":"9248","DOI":"10.3390\/ijms21239248","volume":"21","author":"M Duan","year":"2020","unstructured":"Duan M, Ulibarri J, Liu KJ, Mao P (2020) Role of Nucleotide Excision Repair in Cisplatin Resistance. Int J Mol Sci 21:9248","journal-title":"Int J Mol Sci"},{"key":"6563_CR14","first-page":"507","volume":"18","author":"MA El Baiomy","year":"2017","unstructured":"El Baiomy MA, El Kashef WF (2017) ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy. Asian Pac J Cancer Prev 18:507\u2013513","journal-title":"Asian Pac J Cancer Prev"},{"key":"6563_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41420-024-01817-7","volume":"10","author":"S Erdemir Sayan","year":"2024","unstructured":"Erdemir Sayan S, Sreekumar R, Bhome R, Mirnezami A, Yagci T, Sayan AE (2024) ERCC1 abundance is an indicator of DNA repair-apoptosis decision upon DNA damage. Cell Death Discov 10:47","journal-title":"Cell Death Discov"},{"key":"6563_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917\u2013921","journal-title":"Nature"},{"key":"6563_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.dnarep.2015.05.003","volume":"31","author":"L Farnebo","year":"2015","unstructured":"Farnebo L, Stjernstr\u00f6m A, Fredrikson M, Ansell A, Garvin S, Thunell LK (2015) DNA repair genes XPC, XPD, XRCC1, and XRCC3 are associated with risk and survival of squamous cell carcinoma of the head and neck. DNA Repair 31:64\u201372","journal-title":"DNA Repair"},{"key":"6563_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2005.02.020","volume":"43","author":"A Fautrel","year":"2005","unstructured":"Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Langou\u00ebt S (2005) Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol 43:288\u2013293","journal-title":"J Hepatol"},{"key":"6563_CR18","doi-asserted-by":"publisher","first-page":"810058","DOI":"10.3389\/fonc.2022.810058","volume":"12","author":"S Fischer","year":"2022","unstructured":"Fischer S, Hamed M, Emmert S, Wolkenhauer O, Fuellen G, Thiem A (2022) The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma. Front Oncol 12:810058","journal-title":"Front Oncol"},{"key":"6563_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/cr.2008.6","volume":"18","author":"M Fousteri","year":"2008","unstructured":"Fousteri M, Mullenders LH (2008) Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res 18:73\u201384","journal-title":"Cell Res"},{"key":"6563_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/35094000","volume":"1","author":"EC Friedberg","year":"2001","unstructured":"Friedberg EC (2001) How nucleotide excision repair protects against cancer. Nat Rev Cancer 1:22\u201333","journal-title":"Nat Rev Cancer"},{"key":"6563_CR21","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S et al (2023) Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med 29:2825\u20132834","journal-title":"Nat Med"},{"key":"6563_CR25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jmgm.2016.02.010","volume":"65","author":"F Gentile","year":"2016","unstructured":"Gentile F, Tuszynski JA, Barakat KH (2016) New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy. J Mol Graph Model 65:71\u201382","journal-title":"J Mol Graph Model"},{"key":"6563_CR24","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/cbdd.13660","volume":"95","author":"F Gentile","year":"2020","unstructured":"Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH et al (2020) Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein\u2013protein interaction. Chem Biol Drug Des 95:460\u2013471","journal-title":"Chem Biol Drug Des"},{"key":"6563_CR26","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1200\/JCO-24-01214","volume":"43","author":"DM Geynisman","year":"2025","unstructured":"Geynisman DM, Abbosh PH, Ross E, Zibelman MR, Ghatalia P, Anari F et al (2025) Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1). J Clin Oncol 43:1113\u20131122","journal-title":"J Clin Oncol"},{"key":"6563_CR27","doi-asserted-by":"publisher","first-page":"14186","DOI":"10.3390\/ijms241814186","volume":"24","author":"D Gohil","year":"2023","unstructured":"Gohil D, Sarker AH, Roy R (2023) Base excision repair: mechanisms and impact in biology, disease, and medicine. Int J Mol Sci 24:14186","journal-title":"Int J Mol Sci"},{"key":"6563_CR28","doi-asserted-by":"publisher","first-page":"106724","DOI":"10.1016\/j.biocel.2024.106724","volume":"179","author":"PY Guneri-Sozeri","year":"2025","unstructured":"Guneri-Sozeri PY, Adebali O (2025) Transcription factors, nucleotide excision repair, and cancer: a review of molecular interplay. Int J Biochem Cell Biol 179:106724","journal-title":"Int J Biochem Cell Biol"},{"key":"6563_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"6563_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou P-K (2021) DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Sig Transduct Target Ther 6:254","journal-title":"Sig Transduct Target Ther"},{"key":"6563_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/cells12111475","volume":"12","author":"M-Y Huang","year":"2023","unstructured":"Huang M-Y, Huang Y-J, Cheng T-L, Jhang W-Y, Ke C-C, Chen Y-T et al (2023) XPF\u2013ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer. Cells 12:1475","journal-title":"Cells"},{"key":"6563_CR32","doi-asserted-by":"crossref","unstructured":"Iyer G, Tangen CM, Sarfaty M, Regazzi AM, Lee I-L, Fong M et al (2024) DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: a Correlative Analysis of the SWOG S1314 Trial. JCO Precis Oncol. ;e2400287","DOI":"10.1200\/PO.24.00287"},{"issue":"9","key":"6563_CR36","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1021\/cr980421n","volume":"99","author":"ER Jamieson","year":"1999","unstructured":"Jamieson ER, Lippard SJ (1999) Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev 99(9):2467\u20132498","journal-title":"Chem Rev"},{"key":"6563_CR33","first-page":"4529","volume":"59","author":"H Jiang","year":"1999","unstructured":"Jiang H, Yang L-Y (1999) Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins1. Cancer Res 59:4529\u20134534","journal-title":"Cancer Res"},{"issue":"1","key":"6563_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/mol.112.082347","volume":"84","author":"LP Jordheim","year":"2013","unstructured":"Jordheim LP, Barakat KH, Heinrich-Balard L et al (2013) Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol 84(1):12\u201324","journal-title":"Mol Pharmacol"},{"key":"6563_CR34","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.3390\/cells10113254","volume":"10","author":"J Ka\u017amierczak-Bara\u0144ska","year":"2021","unstructured":"Ka\u017amierczak-Bara\u0144ska J, Boguszewska K, Szewczuk M, Karwowski BT (2021) Effects of 5\u2032,8\u2032-Cyclo-2\u2032-deoxypurines on the base excision repair of clustered DNA lesions in nuclear extracts of the XPC cell line. Cells 10:3254","journal-title":"Cells"},{"key":"6563_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573\u2013584","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6563_CR53","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/php.12641","volume":"93","author":"MG Kemp","year":"2017","unstructured":"Kemp MG, Hu J (2017) PostExcision Events in Human Nucleotide Excision Repair. Photochem Photobiol 93(1):178\u2013191","journal-title":"Photochem Photobiol"},{"key":"6563_CR39","doi-asserted-by":"publisher","first-page":"a012583","DOI":"10.1101\/cshperspect.a012583","volume":"5","author":"HE Krokan","year":"2013","unstructured":"Krokan HE, Bjoras M (2013) Base Excision Repair. Cold Spring Harb Perspect Biol 5:a012583\u2013a012583","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6563_CR9","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.3390\/ijms20236092","volume":"20","author":"T-H Lee","year":"2019","unstructured":"Lee T-H, Kang T-H (2019) DNA Oxidation and Excision Repair Pathways. Int J Mol Sci 20:6092","journal-title":"Int J Mol Sci"},{"key":"6563_CR42","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1158\/1078-0432.CCR-18-1001","volume":"25","author":"Q Li","year":"2019","unstructured":"Li Q, Damish AW, Frazier Z, Liu D, Reznichenko E, Kamburov A et al (2019) ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin Cancer Res 25:977\u2013988","journal-title":"Clin Cancer Res"},{"key":"6563_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.629266","author":"L Li","year":"2021","unstructured":"Li L, Guan Y, Chen X, Yang J, Cheng Y (2021) DNA Repair Pathways in Cancer Therapy and Resistance. Front Pharmacol. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2020.629266. 11-2020","journal-title":"Front Pharmacol"},{"key":"6563_CR43","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y (2023) a new wave of innovations within the DNA damage response. Sig Transduct Target Ther 8:338","journal-title":"Sig Transduct Target Ther"},{"key":"6563_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.freeradbiomed.2025.04.027","volume":"235","author":"L Li","year":"2025","unstructured":"Li L, Xiao M, Zhang L, Zhao S, Zhang G, Wu S et al (2025) Excision repair cross complementation group 1 gene exon 3 skipping isoform presents selective cGAS-STING activation in platinum-sensitive lung adenocarcinoma. Free Radic Biol Med 235:73\u201385","journal-title":"Free Radic Biol Med"},{"key":"6563_CR44","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","volume":"2","author":"D Liu","year":"2016","unstructured":"Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E et al (2016) Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol 2:1094","journal-title":"JAMA Oncol"},{"key":"6563_CR45","doi-asserted-by":"publisher","first-page":"16190","DOI":"10.18632\/oncotarget.7668","volume":"8","author":"L Lopes-Aguiar","year":"2017","unstructured":"Lopes-Aguiar L, Costa EFD, Nogueira GAS, Lima TRP, Visacri MB, Pincinato EC et al (2017) XPD c.934G > A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation. Oncotarget 8:16190\u201316201","journal-title":"Oncotarget"},{"key":"6563_CR46","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355:1152\u20131158","journal-title":"Science"},{"key":"6563_CR48","doi-asserted-by":"crossref","unstructured":"Ma\u0107kowiak B, Ostrowska K, Kulcenty K, Ka\u017amierska J, Ostapowicz J, Nowicka H et al The impact of XPC gene single nucleotide polymorphism rs2228001 on head and neck cancer patients\u2019 response to radiotherapy treatment. Rep Pract Oncol Radiother. 2024;VM\/OJS\/J\/99676.","DOI":"10.5603\/rpor.99676"},{"key":"6563_CR49","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.3390\/cancers16183174","volume":"16","author":"R Manguinhas","year":"2024","unstructured":"Manguinhas R, Serra PA, Gil N, Rosell R, Oliveira NG, Guedes RC (2024a) Novel DNA repair inhibitors targeting XPG to enhance cisplatin therapy in non-small cell lung cancer: insights from in silico and cell-based studies. Cancers 16:3174","journal-title":"Cancers"},{"key":"6563_CR50","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/ijms25021246","volume":"25","author":"R Manguinhas","year":"2024","unstructured":"Manguinhas R, Serra PA, Soares RB, Rosell R, Gil N, Oliveira NG et al (2024b) Unveiling novel ERCC1\u2013XPF complex inhibitors: bridging the gap from in silico exploration to experimental design. IJMS 25:1246","journal-title":"IJMS"},{"key":"6563_CR51","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrm3822","volume":"15","author":"JA Marteijn","year":"2014","unstructured":"Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JHJ (2014) Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol 15:465\u2013481","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6563_CR55","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/jcb.20711","volume":"97","author":"CJ McGurk","year":"2006","unstructured":"McGurk CJ, Cummings M, K\u00f6berle B, Hartley JA, Oliver RT, Masters JR (2006) Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 97:1121\u20131136","journal-title":"J Cell Biochem"},{"key":"6563_CR56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/bjc.2013.303","volume":"109","author":"J Mendoza","year":"2013","unstructured":"Mendoza J, Mart\u00ednez J, Hern\u00e1ndez C, P\u00e9rez-Montiel D, Castro C, Fabi\u00e1n-Morales E et al (2013) Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br J Cancer 109:68\u201375","journal-title":"Br J Cancer"},{"key":"6563_CR75","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1038\/s41467-020-15903-8","volume":"11","author":"Y n Der Weegen","year":"2020","unstructured":"n Der Weegen Y, Golan-Berman H, Mevissen TET, Apelt K, Gonz\u00e1lez-Prieto R, Goedhart J et al (2020) The cooperative action of CSB, CSA, and UVSSA target TFIIH to DNA damage-stalled RNA polymerase II. Nat Commun 11:2104","journal-title":"Nat Commun"},{"issue":"10","key":"6563_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1021\/cb1000444","volume":"5","author":"TM Neher","year":"2010","unstructured":"Neher TM, Shuck SC, Liu JY, Zhang JT, Turchi JJ (2010) Identification of novel small molecule inhibitors of the XPA protein using in  based screening. ACS Chem Biol 5(10):953\u2013965","journal-title":"ACS Chem Biol"},{"issue":"5","key":"6563_CR52","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.molcel.2010.02.009","volume":"37","author":"T Ogi","year":"2010","unstructured":"Ogi T, Limsirichaikul S, Overmeer RM et al (2010) Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol Cell 37(5):714\u2013727","journal-title":"Mol Cell"},{"key":"6563_CR57","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/annonc\/mdw321","volume":"27","author":"KA Olaussen","year":"2016","unstructured":"Olaussen KA, Postel-Vinay S (2016) Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Ann Oncol 27:2004\u20132016","journal-title":"Ann Oncol"},{"key":"6563_CR58","doi-asserted-by":"publisher","first-page":"70","DOI":"10.7150\/jca.10478","volume":"6","author":"A Orlandi","year":"2015","unstructured":"Orlandi A, Di Salvatore M, Bagal\u00e0 C, Basso M, Strippoli A, Plastino F et al (2015) ERCC1 induction after oxaliplatin exposure may depend on KRAS mutational status in colorectal cancer cell line : in vitro veritas. J Cancer 6:70\u201381","journal-title":"J Cancer"},{"key":"6563_CR59","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3389\/fphar.2018.01197","volume":"9","author":"N Pajuelo-Lozano","year":"2018","unstructured":"Pajuelo-Lozano N, Bargiela-Iparraguirre J, Dominguez G, Quiroga AG, Perona R, Sanchez-Perez I (2018) XPA, XPC, and XPD modulate sensitivity in gastric cisplatin resistance cancer cells. Front Pharmacol 9:1197","journal-title":"Front Pharmacol"},{"issue":"5","key":"6563_CR54","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/php.12487","volume":"91","author":"K Paul-Konietzko","year":"2015","unstructured":"Paul-Konietzko K, Thomale J, Arakawa H, Iliakis G (2015) DNA ligases I and III support nucleotide excision repair in DT40 cells with similar efficiency. Photochem Photobiol 91(5):1173\u20131180","journal-title":"Photochem Photobiol"},{"key":"6563_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.eururo.2024.06.018","volume":"86","author":"ER Plimack","year":"2024","unstructured":"Plimack ER, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C et al (2024) Correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 trial. Eur Urol 86:297\u2013300","journal-title":"Eur Urol"},{"key":"6563_CR61","doi-asserted-by":"publisher","first-page":"20567","DOI":"10.1038\/s41598-023-47946-4","volume":"13","author":"A Prosz","year":"2023","unstructured":"Prosz A, Duan H, Tisza V, Sahgal P, Topka S, Klus GT et al (2023) Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. Sci Rep 13:20567","journal-title":"Sci Rep"},{"key":"6563_CR62","doi-asserted-by":"publisher","first-page":"102697","DOI":"10.1016\/j.dnarep.2019.102697","volume":"82","author":"AS Rajkumar-Calkins","year":"2019","unstructured":"Rajkumar-Calkins AS, Szalat R, Dreze M, Khan I, Frazier Z, Reznichenkov E et al (2019) Functional profiling of nucleotide excision repair in breast cancer. DNA Repair 82:102697","journal-title":"DNA Repair"},{"key":"6563_CR63","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/978-94-017-2374-9_12","volume-title":"Multiple Drug Resistance in Cancer 2","author":"E Reed","year":"1998","unstructured":"Reed E (1998) Nucleotide excision repair and anti-cancer chemotherapy. In: Clynes M (ed) Multiple Drug Resistance in Cancer 2. Springer Netherlands, Dordrecht, pp 187\u2013201. http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-94-017-2374-9_12. accessed 18 March 2026"},{"key":"6563_CR64","doi-asserted-by":"publisher","first-page":"14412","DOI":"10.1073\/pnas.1920165117","volume":"117","author":"LK Saha","year":"2020","unstructured":"Saha LK, Wakasugi M, Akter S, Prasad R, Wilson SH, Shimizu N et al (2020) Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells. Proc Natl Acad Sci USA 117:14412\u201314420","journal-title":"Proc Natl Acad Sci USA"},{"key":"6563_CR65","doi-asserted-by":"publisher","first-page":"a012609","DOI":"10.1101\/cshperspect.a012609","volume":"5","author":"OD Scharer","year":"2013","unstructured":"Scharer OD (2013) Nucleotide Excision Repair in Eukaryotes. Cold Spring Harb Perspect Biol 5:a012609\u2013a012609","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"6563_CR66","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.cell.2008.10.045","volume":"135","author":"A Scrima","year":"2008","unstructured":"Scrima A, Kon\u00ed\u010dkov\u00e1 R, Czyzewski BK, Kawasaki Y, Jeffrey PD, Groisman R et al (2008) Structural basis of UV DNA-damage recognition by the DDB1\u2013DDB2 complex. Cell 135:1213\u20131223","journal-title":"Cell"},{"key":"6563_CR67","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1378\/chest.127.3.978","volume":"127","author":"GR Simon","year":"2005","unstructured":"Simon GR, Sharma S, Cantor A, Smith P, Bepler G (2005) ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127:978\u2013983","journal-title":"Chest"},{"key":"6563_CR68","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/s41467-024-45664-7","volume":"15","author":"K Son","year":"2024","unstructured":"Son K, Takhaveev V, Mor V, Yu H, Dillier E, Zilio N et al (2024) Trabectedin derails transcription-coupled nucleotide excision repair to induce DNA breaks in highly transcribed genes. Nat Commun 15:1388","journal-title":"Nat Commun"},{"key":"6563_CR69","doi-asserted-by":"publisher","first-page":"11785","DOI":"10.1038\/s41598-017-08257-7","volume":"7","author":"X Song","year":"2017","unstructured":"Song X, Wang S, Hong X, Li X, Zhao X, Huai C et al (2017) Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer. Sci Rep 7:11785","journal-title":"Sci Rep"},{"key":"6563_CR70","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1097-2765(00)80132-X","volume":"2","author":"K Sugasawa","year":"1998","unstructured":"Sugasawa K, Ng JMY, Masutani C, Van Der Iwai S, Eker APM et al (1998) Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. Mol Cell 2:223\u2013232","journal-title":"Mol Cell"},{"key":"6563_CR71","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM et al (2018) Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. JCO 36:1685\u20131694","journal-title":"JCO"},{"key":"6563_CR72","doi-asserted-by":"publisher","unstructured":"Torgovnick A, Schumacher B (2015) DNA repair mechanisms in cancer development and therapy. Front Genet 6\u20132015. https:\/\/www.frontiersin.org\/journals\/genetics\/articles\/https:\/\/doi.org\/10.3389\/fgene.2015.00157","DOI":"10.3389\/fgene.2015.00157"},{"key":"6563_CR73","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1476-4598-9-248","volume":"9","author":"S Usanova","year":"2010","unstructured":"Usanova S, Pi\u00e9e-Staffa A, Sied U, Thomale J, Schneider A, Kaina B et al (2010) Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9:248","journal-title":"Mol Cancer"},{"key":"6563_CR74","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140\u20131153","journal-title":"Cancer Discov"},{"issue":"4","key":"6563_CR37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4(4):307\u2013320","journal-title":"Nat Rev Drug Discov"},{"key":"6563_CR76","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.3390\/ijms22095008","volume":"22","author":"R Wei","year":"2021","unstructured":"Wei R, Dai H, Zhang J, Shih DJH, Liang Y, Xiao P et al (2021) A Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. IJMS 22:5008","journal-title":"IJMS"},{"key":"6563_CR77","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ijc.20134","volume":"110","author":"C Welsh","year":"2004","unstructured":"Welsh C, Day R, McGurk C, Masters JRW, Wood RD, K\u00f6berle B (2004) Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110:352\u2013361","journal-title":"Int J Cancer"},{"issue":"1","key":"6563_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/cr.2007.116","volume":"18","author":"W Yang","year":"2008","unstructured":"Yang W (2008) Structure and mechanism for DNA lesion recognition. Cell Res 18(1):184\u2013197","journal-title":"Cell Res"},{"key":"6563_CR78","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1158\/1078-0432.CCR-10-2169","volume":"17","author":"M Yin","year":"2011","unstructured":"Yin M, Yan J, Martinez-Balibrea E, Graziano F, Lenz H-J, Kim H-J et al (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res 17:1632\u20131640","journal-title":"Clin Cancer Res"},{"key":"6563_CR79","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3390\/genes16020231","volume":"16","author":"A Zachayus","year":"2025","unstructured":"Zachayus A, Loup-Forest J, Cura V, Poterszman A (2025) Nucleotide excision repair: insights into canonical and emerging functions of the transcription\/DNA repair factor TFIIH. Genes 16:231","journal-title":"Genes"},{"key":"6563_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2025.12832","volume":"29","author":"Z Zhan","year":"2025","unstructured":"Zhan Z, Luo X, Shi J, Chen L, Ye M, Jin X (2025) Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors and potential therapeutic agents (Review). Exp Ther Med 29:1\u201315","journal-title":"Exp Ther Med"},{"key":"6563_CR81","doi-asserted-by":"publisher","first-page":"10702","DOI":"10.1038\/s41598-017-10800-5","volume":"7","author":"R Zhang","year":"2017","unstructured":"Zhang R, Jia M, Xue H, Xu Y, Wang M, Zhu M et al (2017) Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. Sci Rep 7:10702","journal-title":"Sci Rep"},{"key":"6563_CR82","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8127","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Cao J, Meng Y, Qu C, Shen F, Xu L (2018) Overexpression of xeroderma pigmentosum group\u00ef\u00bf\u00bdC decreases the chemotherapeutic sensitivity of colorectal carcinoma cells to cisplatin. Oncol Lett. http:\/\/www.spandidos-publications.com\/https:\/\/doi.org\/10.3892\/ol.2018.8127accessed 27 July 2023","journal-title":"Oncol Lett"},{"key":"6563_CR83","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.3390\/biomedicines11123133","volume":"11","author":"T Zou","year":"2023","unstructured":"Zou T, Liu J-Y, Qin Q, Guo J, Zhou W-Z, Li X-P et al (2023) Role of rs873601 polymorphisms in prognosis of lung cancer patients treated with platinum-based chemotherapy. Biomedicines 11:3133","journal-title":"Biomedicines"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06563-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06563-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:02:12Z","timestamp":1792368132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06563-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":83,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["6563"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06563-0","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that artificial intelligence tools were not used in the preparation or analysis of this manuscript.","order":2,"name":"Ethics","label":"Usage of Artificial Intelligence","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"198"}}